Hardy Baumbach

Hardy Baumbach

Auto-generated profile, based on publicly available information

Hardy Baumbach

Department of Cardiovascular Surgery, Robert-Bosch-Krankenhaus, Stuttgart, Germany

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2019 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
HBHardy Baumbach
Hardy Baumbach
ESEva R. Schairer
Eva R. Schairer
KWKristina Wachter
Kristina Wachter
CRChristian Rustenbach
Christian Rustenbach
SASamir Ahad
Samir Ahad
TSTim Schäufele
Tim Schäufele
Coronary artery disease (CAD) is associated with poorer outcomes after aortic valve replacement (AVR). For high-risk patients with complex CAD, combined transcatheter aortic valve replacement (TAVR) plus off-pump/minimally-invasive coronary artery bypass (OPCAB/MIDCAB) has been proposed. A prospective registry analysis was performed to compare the characteristics and outcomes of patients undergoing TAVR+OP/MIDCAB with those undergoing TAVR plus percutaneous coronary intervention (PCI) and surgical AVR plus coronary artery bypass grafting (CABG) between 2008 and 2015 at a single site in Germany. 464 patients underwent SAVR+CABG, 50 underwent TAVR+OP/MIDCAB, and 112 underwent TAVR+PCI. The mean ages (p < 0.001) and logistic EuroSCOREs (p < 0.001) were similarly higher in TAVR+OP/MIDCAB and TAVR+PCI patients compared to SAVR+CABG patients. Prior cardiac surgery was more common in TAVR+PCI than in TAVR+OP/MIDCAB and SAVR+CABG patients (p < 0.001). Procedural times were shortest (p < 0.001), creatine kinase (muscle brain) levels least elevated (p < 0.001), pericardial tamponade least common (p = 0.027), and length of hospital stay shortest (p = 0.011) in TAVR+PCI, followed by TAVR+OP/MIDCAB and SAVR+CABG patients. In-hospital mortality was highest for TAVR+OP/MIDCAB patients (18.0%) with comparable rates for TAVR+PCI and SAVR+CABG groups (9.0 and 6.9%; p = 0.009). Mortality by 12 months was more probable after TAVR+OP/MIDCAB (HR: 2.17, p = 0.002) and TAVR/PCI (HR: 1.63, p = 0.010) than after SAVR+CABG, with the same true of rehospitalisation (HR: 2.39, p = 0.003 and HR: 1.63, p = 0.033). TAVR+OP/MIDCAB patients share many characteristics with TAVR+PCI patients, with only slightly poorer long-term outcomes. In patients ineligible for SAVR+CABG and TAVR+PCI, hybrid interventions are reasonable second-line options.

26 July 2016 in Health and Quality of Life Outcomes
Verified
Journal Article
Open access
PDF file
KKKlaus Kaier
Klaus Kaier
AGAnja Gutmann
Anja Gutmann
HBHardy Baumbach
Hardy Baumbach
CMConstantin von Zur Mühlen
Constantin von Zur Mühlen
PHPhilip Hehn
Philip Hehn
JRJochen Reinöhl
Jochen Reinöhl
Quality of life (QoL) measurements reported in observational studies are often biased, since patients who failed to improve are more likely to be unable to respond due to death or impairment. In order to observe the development of QoL in patients close to death, we analyzed a set of monthly QoL measurements for a cohort of elderly patients treated for aortic valve stenosis (AS) with special consideration of the effect of distance to death. QoL in 169 elderly patients (age ≥ 75 years), treated either with transcatheter aortic valve replacement (TAVR; n = 92), surgical aortic-valve replacement (n = 70), or drug-based therapy (n = 7), was evaluated using the standardized EQ-5D questionnaire. Over a two-year period, patients were consulted using monthly telephone interviews or outpatient visits, leading to a total of 2463 time points at which QoL values, New York Heart Association (NYHA) Functional Classification and their status of assistance were assessed. Furthermore, post-procedural clinical events and complications were monitored. Linear and ordered logistic regression analyses with random intercept were carried out, taking into account overall trends and distance to death. QoL measures decreased slightly over time, were temporarily impaired at month 1 after the initial episode of hospitalization and decreased substantially at the end of life with a measurable effect starting at the sixth from last follow-up (month) before death. Many clinical complications (bleeding complications, stroke, acute kidney injury) showed an impairment of QoL measurements, but the inclusion of lagged variables demonstrated medium term (three months) QoL impairments for access site bleeding only. All other complications are associated with event-related impairments that decreased dramatically at the second and third follow-up interviews (month) after event. Distance to death shows clear effects on QoL and should be taken into account when analyzing QoL measures in the elderly patients treated for aortic valve stenosis. German Clinical Trial Register Nr. DRKS00000797

1 August 2011 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
HBHardy Baumbach
Hardy Baumbach
SHStephan Hill
Stephan Hill
MHMatthias Hansen
Matthias Hansen
UFUlrich F.W. Franke
Ulrich F.W. Franke

23 April 2016 in The Annals of Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
HBHardy Baumbach
Hardy Baumbach
KWKristina Wachter
Kristina Wachter
RNRagi Nagib
Ragi Nagib
SASamir Ahad
Samir Ahad
RYRashmi Yadav
Rashmi Yadav
UFUlrich Franke
Ulrich Franke

1 June 2009 in Interactive CardioVascular and Thoracic Surgery
Verified
Journal Article
Open access
PDF file
UFUlrich F.W. Franke
Ulrich F.W. Franke
MAMarc Albert
Marc Albert
Christian Jörg RustenbachChristian Jörg Rustenbach
Christian Jörg Rustenbach
HBHardy Baumbach
Hardy Baumbach
The Ross procedure has gained increasing interest for therapy of aortic valve pathologies in young adults because of excellent long-term results. This case report describes the first published experiences of the Ross procedure performed through a minimally invasive access in two consecutive patients. The limited access is associated with only a slightly prolonged aortic cross-clamp time. Consequently, a minimal access method does not result in an increased risk for patients.

8 August 2016 in Journal of Cardiothoracic Surgery
Verified
Journal Article
Open access
PDF file
KWKristina Wachter
Kristina Wachter
SASamir Ahad
Samir Ahad
Christian Jörg RustenbachChristian Jörg Rustenbach
Christian Jörg Rustenbach
UFUlrich F. W. Franke
Ulrich F. W. Franke
HBHardy Baumbach
Hardy Baumbach
Transcatheter aortic valve implantation (TAVI) has proven to be a valid option for patients with severe aortic stenosis who are at high perioperative risk, particularly in patients with previous cardiac surgery. Several patients with previous mitral valve surgery were reported to have been successfully treated with TAVI. Two patients, one with mechanical and one with biological mitral valve prosthesis, presented with symptomatic severe aortic stenosis. After discussion among our multidisciplinary heart team transapical approach and a JenaValve™ prosthesis was used for TAVI. Main reasons were to decrease the perioperative risk, avoid a re-opening of the chest via median sternotomy, and discuss the possible superiority of the JenaValve™ device due to its design. The patients were successfully treated and discharged on the 11th and 14th post-operative day, respectively. Echocardiographic follow up before discharge and up to 2.8 years post-operatively showed excellent results. In conclusion, TAVI in patients with preexisting mitral prostheses-mechanical or biological-is feasible, safe, and effective and offers a valid alternative to conventional aortic valve replacement in this particular re-operation scenario. The JenaValve™ device does not interact with the mitral prosthesis and offers therefore due to its unique design a potential advantage.